ASCO 2003 Session on Sarcoma

This session includes several presentations on GIST.
Link to the ASCO site, then scroll down the page to find and select the desired presentations from this list.

Sarcoma
Robert G Maki, MD, PhD (Discussant)

Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results.
Abstract No: 3271
Robert S Benjamin, MD

Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG.
Abstract No: 3272
Jaap Verweij, MD, PhD

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate.
Abstract No: 3273
George D. Demetri, MD

PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST)
Abstract No: 3274
Michael C Heinrich, MD

Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST)
Abstract No: 3275
Jonathan A. Fletcher, MD

Below is the link to view the ASCO page containing the above presentation links:
ASCO 2003 Sarcoma session